Advancing ASO therapies from development to implementation

Rebecca Schuele,Matthis Synofzik,Holm Graessner,Annemieke Aartsma-Rus
DOI: https://doi.org/10.1038/s41591-024-03217-x
IF: 82.9
2024-09-13
Nature Medicine
Abstract:A novel application of antisense oligonucleotide (ASO) technology, developed to treat a single patient, adds to the growing number of 'personalized' therapies for rare diseases; but pathways to implementation and access are urgently needed.
biochemistry & molecular biology,cell biology,medicine, research & experimental
What problem does this paper attempt to address?